Literature DB >> 1997720

Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice.

W M van Weerden1, G J van Steenbrugge, A van Kreuningen, E P Moerings, F H de Jong, F H Schröder.   

Abstract

The androgen dependent prostatic carcinoma of human origin, PC-82, was used as a model system to investigate the effect of various levels of androgen on the growth of prostatic tumor tissue. Plasma testosterone levels in mice were correlated to tumor growth and intratumor concentrations of testosterone and 5 alpha-dihydrotestosterone. PC-82 tumor burden remained stable at plasma testosterone levels of 0.8 nmol/l., whereas tumor growth occurred at higher levels and tumor regression was observed at lower plasma levels. This critical level of testosterone corresponded with intratumor testosterone and 5 alpha-dihydrotestosterone concentrations of six to 10 and three to four pmol/gm. tissue, respectively, which are significantly above the levels found in castrated non-supplemented animals (3.1 and 1.4 pmol/gm. respectively). This indicates that remaining concentrations of dihydrotestosterone, which amount to two to three times the castrate level, are not stimulatory for tumor growth in the model of the androgen dependent PC-82 tumor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997720     DOI: 10.1016/s0022-5347(17)38409-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Hormonal manipulation of prostatic cancer.

Authors:  F H Schröder
Journal:  BMJ       Date:  1991-12-14

2.  Challenges with luteinizing hormone-releasing hormone agonists: flare and surge.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

3.  Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

4.  Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2003

Review 5.  Testosterone therapy and prostate carcinoma.

Authors:  Ernani Luis Rhoden; Márcio Augusto Averbeck
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

6.  Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines.

Authors:  W M van Weerden; A van Kreuningen; E P Moerings; F H de Jong; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1991

Review 7.  Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field.

Authors:  Juliet A Williams
Journal:  J Clin Med       Date:  2018-03-02       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.